Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer

NCT02074878 is registered in ClinicalTrials.gov with Mothaffar Rimawi as lead sponsor.

NCT NCT02074878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02074878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer
Lead sponsor
Mothaffar Rimawi
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2014
Completion date
May 16, 2017
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer